A compound of formula: or a pharmaceutically acceptable salt thereof; wherein L is bond, (CH 2) n, -CH(CH 3)-, -O-(CH 2) n -, -C -, or -C -NH-(CH 2) n -; n is 1, 2, or 3; R 1 is selected from C 3 -C 7 cycloalkyl optionally substituted once or more than once with a substituent independently selected from hydroxyl, halogen, and C 1 -C 3 alkyl; and bridged C 5 -C 10 cycloalkyl optionally substituted once or more than once with a substituent independently selected from hydroxyl and hydroxyC 1 -C 3 alkyl; R 2 and R 3 are independently selected from H, halogen, and C 1 -C 3 alkyl; R 4 is a N-containing heterocylic non-aromatic ring optionally comprising one or more additional heteroatom(s) selected from N, O and S, wherein said ring is a saturated or unsaturated non-aromatic ring or ring system, which is a 4-, 5-, 6-, or 7-membered monocyclic ring containing 1, 2 or 3 heteroatom(s) selected from O, S and N wherein at least one heteroatom is N, a 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring system containing 1, 2, 3, 4 or 5 heteroatom(s) selected from O, S and N wherein at least one heteroatom is N, or a 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system containing 1, 2, 3, 4, 5, 6 or 7 heteroatom(s) selected from O, S and N wherein at least one heteroatom is N; where the N and S can also optionally be oxidized to various oxidation states; and the ring can be a fused, bridged or spirocyclic ring; and wherein said ring is optionally substituted once or more than once with R 7; each R 7 is independently selected from C 1 -C 3 alkyl, hydroxyC 1 -C 3 alkyl, haloC 1 -C 3 alkyl, C 1 -C 3 alkoxyC 1 -C 3 alkyl, haloC 1 -C 3 alkoxyC 1 -C 3 alkyl, C 2 -C 4 alkynyl, cyanoC 1 -C 3 alkyl, and (CH 2) m -R 8; m is 0, 1, 2 or 3; R 8 is selected from a 4-, 5-, or 6-membered saturated or unsaturated non-aromatic heterocyclic ring comprising one or more heteroatom(s) selected from N, O and S, said ring being optionally substituted once or more than once with a substituent independently selected from oxo, SO 2 C 1 -C 3 alkyl, and haloC 1 -C 3 alkyl; and a C 3 -C 6 cycloalkyl optionally substituted once or more than once with halo. or a pharmaceutically acceptable salt thereof; wherein L is bond, (CH 2) n, -CH(CH 3)-, -O-(CH 2) n -, -C -, or -C -NH-(CH 2) n -; n is 1, 2, or 3; R 1 is selected from C 3 -C 7 cycloalkyl optionally substituted once or more than once with a substituent independently selected from hydroxyl, halogen, and C 1 -C 3 alkyl; and bridged C 5 -C 10 cycloalkyl optionally substituted once or more than once with a substituent independently selected from hydroxyl and hydroxyC 1 -C 3 alkyl; R 2 and R 3 are independently selected from H, halogen, and C 1 -C 3 alkyl; R 4 is a N-containing heterocylic non-aromatic ring optionally comprising one or more additional heteroatom(s) selected from N, O and S, wherein said ring is a saturated or unsaturated non-aromatic ring or ring system, which is a 4-, 5-, 6-, or 7-membered monocyclic ring containing 1, 2 or 3 heteroatom(s) selected from O, S and N wherein at least one heteroatom is N, a 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring system containing 1, 2, 3, 4 or 5 heteroatom(s) selected from O, S and N wherein at least one heteroatom is N, or a 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system containing 1, 2, 3, 4, 5, 6 or 7 heteroatom(s) selected from O, S and N wherein at least one heteroatom is N; where the N and S can also optionally be oxidized to various oxidation states; and the ring can be a fused, bridged or spirocyclic ring; and wherein said ring is optionally substituted once or more than once with R 7; each R 7 is independently selected from C 1 -C 3 alkyl, hydroxyC 1 -C 3 alkyl, haloC 1 -C 3 alkyl, C 1 -C 3 alkoxyC 1 -C 3 alkyl, haloC 1 -C 3 alkoxyC 1 -C 3 alkyl, C 2 -C 4 alkynyl, cyanoC 1 -C 3 alkyl, and (CH 2) m -R 8; m is 0, 1, 2 or 3; R 8 is selected from a 4-, 5-, or 6-membered saturated or unsaturated non-aromatic heterocyclic ring comprising one or more heteroatom(s) selected from N, O and S, said ring being optionally substituted once or more than once with a substituent independently selected from oxo, SO 2 C 1 -C 3 alkyl, and haloC 1 -C 3 alkyl; and a C 3 -C 6 cycloalkyl optionally substituted once or more than once with halo.